Drug intelligence / Profile preview

WXD171

Development stage: Preclinical
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

WXD171 is a specific strain of *Limosilactobacillus reuteri* (formerly *Lactobacillus reuteri*) utilized as a probiotic delivery vehicle for the development of oral vaccines. It was selected for its robust tolerance to the gastrointestinal environment, superior mucosal adhesion, and intrinsic antimicrobial activities. In preclinical research, WXD171 has been engineered to express *Staphylococcus aureus* antigens, most notably the iron-regulated surface determinant B (IsdB), to create a live oral vaccine candidate (WXD171-IsdB). This platform is designed to stimulate gut-associated lymphoid tissues (GALT), inducing mucosal immune responses characterized by increased production of secretory IgA and interleukin-17A (IL-17A). This vaccination strategy has demonstrated prophylactic potential against localized *S. aureus* infections, such as pneumonia and skin infections, as well as systemic conditions like sepsis.

Other names: Limosilactobacillus reuteri WXD171L. reuteri WXD171

Targets

IsdB (Iron surface determinant B)

Beyond the preview

Go deeper on WXD171.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WXD171.

Explore the full profile